Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR5220)
Drug Name
Terazosin
Synonyms
Blavin; Flumarc; Fosfomic; Hytracin; Hytrin; Terazosabb; Terazosina; Terazosine; Terazosinum; Vasomet; Trazosin HCl; A 45975; Abbott 45975; A-45975; Hytrin (TN); Terazosabb (TN); Terazosin (INN); Terazosin [INN:BAN]; Terazosina [INN-Spanish]; Terazosine [INN-French]; Terazosinum [INN-Latin]; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](tetrahydrofuran-2-yl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine; 6,7-bis(methyloxy)-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; 6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine
Indication Prostatic hyperplasia [ICD11: GA90] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 387.4 Topological Polar Surface Area 103
Heavy Atom Count 28 Rotatable Bond Count 4
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 8
Cross-matching ID
PubChem CID
5401
ChEBI ID
CHEBI:9445
CAS Number
63590-64-7
TTD Drug ID
D0P9RF
Formula
C19H25N5O4
Canonical SMILES
COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC
InChI
InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)
InChIKey
VCKUSRYTPJJLNI-UHFFFAOYSA-N
The Predicted Metabolic Roadmap of This Drug
The Full List of Predicted Drug Metabolites (PDM) of This Drug
PDM Name PDM ID PubChem ID Reaction PDM Level Biosystem
Formaldehyde DM001748
712
Oxidation - O-Dealkylation from CyProduct 1 Human
Terazosin M1 PDM014731 N. A. Conjugation - Glucuronidation of primary aromatic amine 1 Human
Terazosin M10 PDM014738 N. A. Oxidation - Hydroxylation of heteroalicyclic secondary carbon 1 Human
Terazosin M11 PDM014739 N. A. Oxidation - Aromatic hydroxylation of fused benzene ring 1 Human
Terazosin M12 PDM014447
66546594
Oxidation - N-Hydroxylation of primary arylamine AndFromCyProduct 1 Human
Terazosin M2 PDM014732 N. A. Oxidation - N-Dealkylation of mixed tertiary amine 1 Human
Terazosin M3 PDM014462
136264171
Oxidation - O-Dealkylation AndFromCyProduct 1 Human
Terazosin M4 PDM014451
72941636
Oxidation - O-Dealkylation AndFromCyProduct 1 Human
Terazosin M5 PDM014733 N. A. Oxidation - Hydroxylation of heteroalicyclic secondary carbon 1 Human
Terazosin M6 PDM014734 N. A. Oxidation - Hydroxylation of heteroalicyclic secondary carbon 1 Human
Terazosin M9 PDM014737 N. A. Oxidation - Hydroxylation of heteroalicyclic secondary carbon 1 Human
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 3A1 (Cyp3a1) DMEN096 Rattus norvegicus
CP3A1_RAT
1.14.14.1
[2]
Cytochrome P450 3A2 (Cyp3a2) DMEN097 Rattus norvegicus
CP3A2_RAT
1.14.14.1
[2]
References
1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7302).
2 Pharmacokinetic and pharmacodynamic consequences of inhibition of terazosin metabolism via CYP3A1 and/or 3A2 by DA-8159, an erectogenic, in rats

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.